Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Pfizer on Monday announced it is halting development of a daily weight loss pill after one patient experienced a liver injury ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Im Ringen um den stark umkämpften Markt für Adipositas-Medikamente hat der US-Pharmakonzern Pfizer einen Rückschlag erlitten ...

Pfizer Inc. dejará de desarrollar una píldora contra la obesidad que ha sido seguida de cerca por los inversores, un duro ...